Sun Pharma arms to pay $200 mln to settle antitrust case in Pennsylvania, US
This story was originally published at 19:04 IST on 24 July 2025
Register to read our real-time news.Informist, Thursday, Jul. 24, 2025
--Sun Pharma arms settle In re generic antitrust case in Pennsylvania, US
--Sun Pharma arms to pay $200 mln for full release of all claims against cos
MUMBAI – Sun Pharmaceutial Industries Ltd.'s subsidiaries--Sun Pharmaceutical Industries Inc. and Taro Pharmaceuticals USA Inc.--have settled an antitrust litigation case related to generic pharmaceuticals pricing in Pennsylvania, the US. The Indian company's subsidiaries will pay $200 million to "End Purchaser Plaintiffs" to release all claims against the subsidiaries, according to an exchange filing Thursday.
Sun Pharmaceutical said the settlement amount can reduce if "more than a certain percentage of the total insured class members opt out of the putative class". The settlement amount of $200 million translates to over INR 17 billion, which is nearly 16% of Sun Pharma's consolidated net profit in 2024-25 (Apr-Mar).
During FY25, Sun Pharma had reported a consolidated net profit of INR 109.29 bln on a consolidated revenue of INR 525.78 billion. Thursday, shares of the company closed at INR 1,692 per share on the National Stock Exchange, up 0.6%. End
US$1 = INR 86.41
Reported by Anshul Choudhary
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
